<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pathophysiologic classification of the main monoclonal gammopathy of clinical significance-related disorders</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pathophysiologic classification of the main monoclonal gammopathy of clinical significance-related disorders</h1>
<div class="graphic"><div class="figure"><div class="ttl">Pathophysiologic classification of the main monoclonal gammopathy of clinical significance-related disorders</div><div class="cntnt"><table cellspacing="0"><colgroup width="25%"></colgroup><colgroup width="20%"></colgroup><colgroup width="25%"></colgroup><colgroup width="30%"></colgroup> <tbody> <tr> <td class="subtitle1"> </td> <td class="subtitle1">Monoclonal immunoglobulin deposits</td> <td class="subtitle1">Main characteristics of monoclonal gammopathy</td> <td class="subtitle1">Main involved organ(s)</td> </tr> <tr> <td class="subtitle2_left" colspan="4">Immunoglobulin deposition in tissue*</td> </tr> <tr> <td class="indent1">AL amyloidosis</td> <td>Fibrillar</td> <td> <ul> <li>Lambda LC (75%), kappa LC (25%), IgM (&lt;10%) </li> </ul> </td> <td> <ul> <li>Systemic </li> <li>Heart (80%), kidney (70%) </li> </ul> </td> </tr> <tr> <td class="indent1">Type I cryoglobulinemia</td> <td>Microtubular/crystalline</td> <td> <ul> <li>IgG or IgM </li> </ul> </td> <td> <ul> <li>Systemic </li> <li>Skin +++, kidney, peripheral nerve, systemic symptoms (crystal-cryoglobulin) </li> </ul> </td> </tr> <tr> <td class="indent1">Immunotactoid glomerulopathy/GOMMID</td> <td>Microtubular</td> <td> <ul> <li>CLL-like clonal B cell proliferation (50%) </li> </ul> </td> <td> <ul> <li>Kidney </li> </ul> </td> </tr> <tr> <td class="indent1">Acquired Fanconi syndrome</td> <td>Crystalline</td> <td> <ul> <li>Kappa LC (&gt;90%, mostly Vk1) </li> </ul> </td> <td> <ul> <li>Kidney (proximal tubulopathy) </li> </ul> </td> </tr> <tr> <td class="indent1">Crystal storing histiocytosis</td> <td>Crystalline</td> <td> <ul> <li>Kappa LC </li> </ul> </td> <td> <ul> <li>Systemic (kidney, cornea, joints, lymphoid tissue) </li> </ul> </td> </tr> <tr> <td class="indent1">Crystalline keratopathy</td> <td>Crystalline</td> <td> <ul> <li>IgG </li> </ul> </td> <td> <ul> <li>Cornea </li> </ul> </td> </tr> <tr> <td class="indent1">Monoclonal immunoglobulin deposition disease (MIDD)</td> <td>Non-organized</td> <td> <ul> <li>LCDD: LC only <ul> <li>Usually kappa LC (80%, Vk1 and Vk4) </li> </ul> </li> <li>HCDD: truncated HC only <ul> <li>Mostly gamma (gamma-1 and gamma-3), alpha, delta </li> </ul> </li> <li>LHCDD: LC plus truncated HC </li> </ul> </td> <td> <ul> <li>Systemic </li> <li>Kidney (approximately 100%, glomerular and tubular basement membrane), liver (30%), heart (30%) </li> </ul> </td> </tr> <tr> <td class="indent1">Proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID)</td> <td>Non-organized</td> <td> <ul> <li>Usually IgG3 </li> </ul> </td> <td> <ul> <li>Kidney </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1">Macroglobulinosis</td> <td>Non-organized</td> <td> <ul> <li>IgM </li> </ul> </td> <td> <ul> <li>Skin (dermis) </li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="4">Autoantibody activity</td> </tr> <tr> <td class="indent1">Type II mixed cryoglobulinemia<sup>¶</sup></td> <td>Rheumatoid</td> <td> <ul> <li>IgM </li> </ul> </td> <td> <ul> <li>Immune complex-mediated vasculitis </li> <li>Skin +++, kidney, peripheral nerve </li> <li>May be systemic </li> </ul> </td> </tr> <tr> <td class="indent1">C1 inhibitor deficiency</td> <td>C1 inhibitor</td> <td> </td> <td> <ul> <li>Angioedema </li> </ul> </td> </tr> <tr> <td class="indent1">Von Willebrand (vW) disease</td> <td>vW factor</td> <td> </td> <td> <ul> <li>Bleeding </li> </ul> </td> </tr> <tr> <td class="indent1">Bullous skin diseases</td> <td>Dermo-epidermal junction (collagen VII)</td> <td> </td> <td> <ul> <li>Skin </li> </ul> </td> </tr> <tr> <td class="indent1">Xanthomatosis</td> <td>Various lipoproteins</td> <td> <ul> <li>Usually IgG </li> </ul> </td> <td> <ul> <li>Cholesterol accumulation in macrophages </li> <li>Skin and tendons </li> <li>Other localizations (necrobiotic xanthogranumathosis) </li> </ul> </td> </tr> <tr> <td class="indent1">Cold agglutinin disease</td> <td>Red blood cell (Ii)</td> <td> <ul> <li>IgM </li> </ul> </td> <td> <ul> <li>Cold-induced skin manifestations plus intravascular hemolysis </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1">IgM associated peripheral neuropathy</td> <td> <p>Myelin associated glycoprotein (MAG) +++</p> Gangliosides </td> <td> <ul> <li>IgM </li> </ul> </td> <td> <ul> <li>Peripheral nerve </li> <li>Ataxic polyneuropathy (anti-MAG) </li> <li>CANOMAD </li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="4">CAP<sup>¶</sup> activation</td> </tr> <tr> <td class="indent1">C3 glomerulonephritis</td> <td> <p>Mechanism to be determined</p> Autoantibody activity against CAP regulator protein (factor H) in some cases </td> <td> <ul> <li>IgG </li> </ul> </td> <td> <ul> <li>Kidney only </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1">Atypical hemolytic-uremic syndrome (HUS)</td> <td> <p>Mechanism to be determined</p> Autoantibody activity against CAP regulator protein (factor H) in some cases </td> <td> <ul> <li>IgG </li> </ul> </td> <td> <ul> <li>Systemic </li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="4">Cytokine-mediated</td> </tr> <tr class="divider_bottom"> <td class="indent1">POEMS syndrome</td> <td>Vascular endothelial growth factor</td> <td> <ul> <li>Lambda LC (approximately 100%) </li> <li>IgA (50%) </li> <li>V-gamma-1 (100%) </li> <li>Osteosclerotic bone lesions </li> </ul> </td> <td> <ul> <li>Peripheral nerve (100%) </li> <li>Various other manifestations </li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="4">Unknown mechanism</td> </tr> <tr> <td class="indent1">Systemic capillary leak syndrome</td> <td> </td> <td> <ul> <li>IgG, IgA (rare) </li> </ul> </td> <td> <ul> <li>Systemic </li> </ul> </td> </tr> <tr> <td class="indent1">TEMPI syndrome</td> <td> </td> <td> <ul> <li>IgG </li> </ul> </td> <td> <ul> <li>Systemic </li> </ul> </td> </tr> <tr> <td class="indent1">Neutrophilic dermatosis<sup>Δ</sup></td> <td> </td> <td> <ul> <li>IgA (&gt;80%; except Sweet's syndrome) </li> </ul> </td> <td> <ul> <li>Skin +++ </li> <li>Different types and different associated manifestations </li> </ul> </td> </tr> <tr> <td class="indent1">Acquired cutis laxa</td> <td> </td> <td> <ul> <li>Usually IgG </li> <li>Association with gamma HCDD </li> </ul> </td> <td> <ul> <li>Skin +++ </li> <li>Other manifestations (lung, digestive tract) </li> </ul> </td> </tr> <tr> <td class="indent1">Scleromyxedema</td> <td> </td> <td> <ul> <li>IgG with slow electrophoretic mobility </li> </ul> </td> <td> <ul> <li>Skin +++ </li> <li>Other localizations </li> </ul> </td> </tr> <tr> <td class="indent1">Scleredema</td> <td> </td> <td> <ul> <li>IgG </li> </ul> </td> <td> <ul> <li>Skin only </li> </ul> </td> </tr> <tr> <td class="indent1">Schnitzler's syndrome</td> <td>Acquired auto-inflammatory syndrome by IL-1 deregulation?</td> <td> <ul> <li>IgM </li> </ul> </td> <td> <ul> <li>Skin +++ </li> <li>Systemic symptoms </li> <li>Osteosclerotic bone lesions </li> </ul> </td> </tr> <tr> <td class="indent1">Sporadic late onset nemaline myopathy (SLONM)</td> <td> </td> <td> </td> <td> <ul> <li>Exclusively muscles (skeletal and possibly cardiac) </li> </ul> </td> </tr> </tbody></table></div><div class="graphic_footnotes">MGCS: monoclonal gammopathy of clinical significance; AL amyloidosis: immunoglobulin light chain amyloidosis; LC: light chain; IgM: immunoglobulin M; IgG: immunoglobulin G; GOMMID: glomerulonephritis with organized microtubular monoclonal immunoglobulin deposits; CLL: chronic lymphocytic leukemia; LCDD: light chain deposition disease; HCDD: heavy chain deposition disease; HC: heavy chain; LHCDD: light and heavy chain deposition disease; CANOMAD: Chronic Ataxic Neuropathy, Ophthalmoplegia, Monoclonal IgM protein, cold Agglutinins, and Disialosyl antibodies; CAP: complement alternative pathway; POEMS: Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal gammopathy, and Skin changes; IgA: immunoglobulin A; TEMPI: Telangiectasias, Erythrocytosis with elevated erythropoietin level, Monoclonal gammopathy, Perinephric fluid collection, and Intrapulmonary shunting; IL-1: interleukin 1.<br/>* AL amyloidosis is the most frequent type with an incidence of about 10/million inhabitants/per year in Western countries. MIDD incidence is estimated to be 10-fold lower. Other types of MGCS due to deposition of monoclonal Ig are rare (type I cryoglobulinemia, PGNMID), even scarcer (Fanconi syndrome) or exceptional (macroglobulinosis, crystalline keratopathy).<br/>¶ A type II mixed cryoglobulinemia was observed in about 10% of patients with chronic virus C infection.<br/>Δ Including pyoderma gangrenosum, Sweet's syndrome, subcorneal pustular dermatosis, and erythema elevatum diutinum.</div><div class="graphic_reference">Republished with permission of the American Society of Hematology, from: Fermand JP, Bridoux F, Dispenzieri A, et al. Monoclonal gammopathy of clinical significance: A novel concept with therapeutic implications. Blood 2018; permission conveyed through Copyright Clearance Center, Inc. Copyright © 2018.</div><div id="graphicVersion">Graphic 118787 Version 6.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
